Remove Innovation Remove Ischemia Remove Stenosis
article thumbnail

Cleerly Launches Cleerly ISCHEMIA Solution for Heart Disease Analysis

DAIC

milla1cf Tue, 01/09/2024 - 11:32 January 9, 2024 — Cleerly , the company working to create a new standard of care for the diagnosis of heart disease, announced the launch of Cleerly ISCHEMIA , which recently received U.S. Cleerly ISCHEMIA is a transformative addition poised to reshape the landscape of cardiac care.”

Ischemia 119
article thumbnail

Results of CERTAIN Study Demonstrate Prominent Effects of Cleerly Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease

DAIC

Previous to GWU, Earls served as Medical Director and Vice President at Fairfax Radiological Consultants (FRC) in Fairfax, VA, where he was an early innovator and clinical adopter of coronary CT angiography. High Diagnostic Accuracy Of AI-Ischemia in Comparison To PET, FFR-CT, SPECT, and Invasive FFR: A PACIFIC Sub-Study.

article thumbnail

Cleerly Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System

DAIC

The CAD Staging System is a noninvasive imaging-based investigational software device that analyzes important and actionable features of coronary atherosclerosis, stenosis and ischemia. Cleerly’s mission extends beyond innovation; it is a commitment to saving lives by revolutionizing the prevention and treatment of heart disease.

article thumbnail

Abstract 154: Clustered Vascular Endotelial Growth Factor Nanoparticles Biomaterial for the Treatment of Moyamoya Disease

Stroke Journal

Introduction:Cerebrovascular ischemia poses a substantial neurological threat due to cerebral artery constriction. Innovative solutions, such as Vascular Endothelial Growth Factor (VEGF)-infused hydrogel biomaterials, have emerged. Stroke, Volume 55, Issue Suppl_1 , Page A154-A154, February 1, 2024.

article thumbnail

PCI for stable angina : Sham trials are welcome, but not OMT shaming trials !

Dr. S. Venkatesan MD

Likelihood of truth : High The flamboyant genius of Andreas Roland Gruntzig, from Zurich gifted us the path-breaking treatment modality for coronary stenosis five decades ago. ORBITA-1 was an excellent and Innovative trial, that answered the above query without any doubt , that PCI has no add on value over medical therapy in chronic CAD.

Angina 52
article thumbnail

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

DAIC

24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m. ET Main Tent (Hall B1) This session offers more insights from key clinical trials presented at ACC.24 24 and find out what it all means for your patients.

article thumbnail

HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients

DAIC

6 This novel study marks a significant milestone in the field, evaluating the effectiveness of FFR CT in detecting ischemia-producing coronary stenosis in patients with severe PAD. Diagnosis and treatment of ischemia-producing coronary stenoses improves 5-year survival of patients undergoing major vascular surgery.”